Clinical trial / 1997
Oral MSG challenge in sensitive individuals increased symptom severity and specific symptoms like headache and numbness compared to placebo.
In 61 self-identified MSG-sensitive subjects, oral challenges were conducted with MSG or placebo, followed by rechallenge with varying doses (placebo, 1.25, 2.5, and 5 gm MSG) in those reacting to a single agent. On initial challenge, 29.5% responded to neither, 9.8% to both, 24.6% to placebo, and 36.1% to MSG (p = 0.324). Total and average symptom severity scores were higher after MSG (374 and 80) than placebo (232 and 56; p = 0.026 and 0.018). Headache, muscle tightness, numbness/tingling, general weakness, and flushing were significantly more frequent after MSG, with an apparent threshold dose of 2.5 gm MSG.
- Study type
- Double-blind randomized crossover oral challenge study
- Who was studied
- 61 self-identified MSG-sensitive subjects
- What was measured
- Reproduction of specific symptoms (>2 symptoms) and symptom severity
THE PAPER
The monosodium glutamate symptom complex: assessment in a double-blind, placebo-controlled, randomized study.
Yang WH, Drouin MA, Herbert M, Mao Y, Karsh J. J Allergy Clin Immunol, 1997.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.